Page last updated: 2024-11-04

1-o-hexadecyl-2-o-methylglycerol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID1380
CHEMBL ID1886638
SCHEMBL ID194905
MeSH IDM0164390

Synonyms (55)

Synonym
CBIOL_001902
1-propanol, 3-(hexadecyloxy)-2-methoxy-
1-o-hexadecyl-2-o-rac-glycerol
3-hexadecoxy-2-methoxy-propan-1-ol
BIO1_001166
BIO1_000677
BIO2_000579
BIO1_000188
BIO2_000099
hxmg
IDI1_033849
NCGC00161338-02
NCGC00161338-01
KBIOSS_000099
KBIO3_000198
KBIO2_000099
KBIO2_005235
KBIOGR_000099
KBIO2_002667
KBIO3_000197
BSPBIO_001379
NCGC00161338-03
H-1842
HMS1989E21
BML2-F12
HMS1791E21
HMS1361E21
111188-59-1
3-hexadecoxy-2-methoxypropan-1-ol
1-o-hexadecyl-2-o-methyl-rac-glycerol
1-propanol, 3-(hexadecyloxy)-2-methoxy-, (+-)-
1-o-palmityl-2-o-methylglycerol
1-o-hexadecyl-2-o-methylglycerol
120964-49-0
hexadecyl methyl glycerol
AKOS017343585
SCHEMBL194905
3-(hexadecyloxy)-2-methoxy-1-propanol
3-(hexadecyloxy)-2-methoxypropanol
3-(hexadecyloxy)-2-methoxy propanol
XAWCMDFDFNRKGK-UHFFFAOYSA-N
3-(hexadecyloxy)-2methoxy-1-propanol
CHEMBL1886638
84337-41-7
(+/-)1-o-hexadecyl-2-o-methylglycerol
HMS3402E21
1-o-hexadecyl-3-o-methyl-rac-glycerol
J-002538
mfcd00079344
DTXSID70912020
FT-0718763
3-(hexadecyloxy)-2-methoxypropan-1-ol
rac-1-o-hexadecyl-2-o-methylglycerol
CS-0137956
HY-134080
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency37.68580.531815.435837.6858AID504845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.76)18.7374
1990's12 (57.14)18.2507
2000's3 (14.29)29.6817
2010's3 (14.29)24.3611
2020's2 (9.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.35 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index5.61 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]